Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 19 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
13(68.4%)
Phase 2
4(21.1%)
N/A
1(5.3%)
Phase 3
1(5.3%)
19Total
Phase 1(13)
Phase 2(4)
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT07362940Phase 1Recruiting

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

Role: lead

NCT07308782Phase 2Recruiting

A Phase Ⅱa Clinical Study of CL-197 Capsules

Role: lead

NCT06991634Phase 1Completed

A Study to Evaluate the Pharmacokinetics and Safety of Azvudine Tablets in Healthy Adult Subjects and Healthy Elderly Subjects

Role: lead

NCT07231068Phase 1Recruiting

A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation

Role: lead

NCT07229898Phase 1Recruiting

A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors

Role: lead

NCT07002242Phase 1Completed

A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Aluvia

Role: lead

NCT07001488Phase 1Completed

A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV)

Role: lead

NCT07002229Phase 1Completed

A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG)

Role: lead

NCT07002268Phase 1Completed

A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)

Role: lead

NCT07001501Phase 1Completed

A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Itraconazole Capsules (ICZ)

Role: lead

NCT07001436Phase 1Recruiting

A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insufficiency and in Healthy Subjects

Role: lead

NCT07002255Phase 1Completed

A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF)

Role: lead

NCT07002281Phase 1Completed

[14C] Mass Balance Clinical Trial of Azvudine in Healthy Male Subjects

Role: lead

NCT05944848Phase 1Completed

A Study of CL-197 Capsules in Healthy Participants

Role: lead

NCT05682599Phase 2Unknown

Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China

Role: collaborator

NCT05633433Phase 2Unknown

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19

Role: collaborator

NCT04425772Not ApplicableUnknown

A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19)

Role: lead

NCT04303598Phase 3Unknown

Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients

Role: lead

NCT04109183Phase 2Completed

A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment

Role: lead

All 19 trials loaded